Preparation of Whole Bone Marrow for Mass Cytometry Analysis of Neutrophil-lineage Cells
June 19th, 2019
9.2K views
Here, we present a protocol to process fresh bone marrow (BM) isolated from mouse or human for high-dimensional mass cytometry (Cytometry by Time-Of-Flight, CyTOF) analysis of neutrophil-lineage cells.
Overview
This protocol outlines a method for processing fresh bone marrow from mouse or human sources for high-dimensional mass cytometry analysis of neutrophil-lineage cells. It aims to preserve the integrity of short-lived myeloid cells, facilitating the study of rare immune cell populations.
Key Study Components
Area of Science
- Mass cytometry
- Bone marrow analysis
- Neutrophil-lineage cells
Background
- Conventional sample preparation often loses critical information.
- Short-lived myeloid cells are challenging to study due to their rapid degradation.
- Mass cytometry allows for the identification of previously underappreciated immune cells.
- This protocol can be adapted for use with other tissue types, such as solid tumors.
Purpose of Study
- To provide a user-friendly protocol for bone marrow isolation.
- To enable the analysis of rare neutrophil-lineage subsets.
- To enhance the understanding of immune cell populations in various diseases.
Methods Used
- Isolation of fresh bone marrow from mouse or human sources.
- Application of mass cytometry techniques.
- Preservation of cell integrity during processing.
- Preparation of reagents prior to protocol execution.
Main Results
- The protocol successfully preserves the integrity of short-lived myeloid cells.
- Facilitates the identification of rare neutrophil-lineage cells.
- Demonstrates applicability to other tissue types.
- Provides a simplified approach for researchers.
Conclusions
- This protocol is effective for high-dimensional analysis of bone marrow cells.
- It opens avenues for studying underappreciated immune cells.
- Future applications may extend to various disease contexts.
Frequently Asked Questions
What is the main advantage of this protocol?
It preserves the integrity of short-lived myeloid cells, allowing for better analysis of rare immune populations.
Can this protocol be used for human samples?
Yes, the protocol is applicable for both mouse and human bone marrow samples.
How does mass cytometry benefit the analysis?
Mass cytometry allows for high-dimensional analysis, enabling the identification of previously overlooked cell types.
Is the protocol user-friendly?
Yes, it has been simplified to make it accessible, though practice may be needed.
What types of cells can be analyzed using this method?
The method is designed to analyze neutrophil-lineage cells and other myeloid populations.
Can this protocol be adapted for other tissues?
Yes, it can be applied to other tissue types, including solid tumors.
Executive Industry Relevance
Preserving short-lived myeloid cells in whole bone marrow enables discovery of rare neutrophil-lineage populations that are lost in conventional preparation. This protocol supports target validation by revealing previously unappreciated immune subsets with implications for hematologic malignancies and inflammatory diseases. The method enhances predictive confidence in early discovery by maintaining cellular integrity for high-dimensional mass cytometry analysis.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses by preserving neutrophil-lineage cells that co-express stem and progenitor markers.
- Operational Value: Reduces biological de-risking through detection of rare cell populations missed in Ly6G-depleted studies.
- Scientific Value: Supports portfolio triage by identifying novel cell populations for functional validation in disease models.
Screening & Assay Development
- Scientific Value: Prepares validated biological systems for downstream CyTOF analysis using a 33-parameter panel to quantify surface marker expression.
- Operational Value: Ensures assay standardization and reproducibility through standardized bone marrow harvest and staining steps.
- Scientific Value: Enables reliable compound evaluation by preserving viability of short-lived myeloid cells during drug screening.
Translational & Preclinical Research
- Scientific Value: Provides disease-relevant system for investigating whole bone marrow defects in leukemia and blood disorders.
- Operational Value: Ensures translational continuity from discovery to preclinical validation via preserved neutrophil-lineage subsets.
- Scientific Value: Supports mechanistic de-risking by linking surface marker profiles to neutrophil-lineage identity independent of Ly6G expression.
Pipeline & Workflow Integration
The method fits within the discovery continuum from early target identification to preclinical validation by enabling high-resolution immune profiling of bone marrow.
- Discovery Biology: Supports hypothesis testing and pathway clarification by revealing novel neutrophil-lineage populations with stem-like markers.
- Screening: Delivers assay readiness and quantitative outputs through standardized cell preparation and mass cytometry staining.
- Analytics: Enables comparative analysis via viSNE clustering and dimensional reduction of 33-parameter CyTOF data.
- Translational Research: Connects to preclinical continuity by preserving cells functional for downstream flow cytometry isolation and assays.
- Enterprise Reuse: Establishes a reusable capability for bone marrow preparation applicable across solid tumor and hematologic disease models.
Operational & Enterprise Impact
- Scientific Value: Predictive confidence through detection of previously unknown neutrophil-lineage cell populations.
- Operational Value: Standardization and reproducibility via defined harvest, lysis, staining, and fixation steps.
- Strategic Value: Better go/no-go decisions by reducing late-stage biological risk through early immune subset discovery.
- Portfolio Impact: Risk-adjusted prioritization by identifying novel targets for functional validation in disease contexts.
Implementation Considerations
- Requires expertise in bone marrow harvest and sterile surgical technique from murine models.
- Depends on mass cytometry instrumentation and access to metal-conjugated antibody panels.
- Necessitates cross-team standardization for consistent cell viability and staining efficiency.
- Involves adaptation considerations when applying to human samples or solid tumor tissues.
- Limited by the need for rapid processing and cold maintenance to preserve short-lived myeloid cell integrity.
Biopharma FAQs
Why does preserving neutrophil-lineage cells matter for target validation?
Conventional preparation loses short-lived myeloid cells, obscuring rare populations that co-express neutrophil and stem cell markers. This protocol preserves these cells, enabling discovery of novel targets missed in Ly6G-depleted studies. Retaining these subsets improves target confidence by revealing biologically relevant immune subsets in bone marrow.
How does isolating whole bone marrow fit the discovery pipeline?
The protocol enables acquisition of viable myeloid subsets directly from fresh bone marrow without prior enrichment or depletion. This maintains physiological context and cellular interactions lost in fractionated samples. Preserving the whole marrow supports early discovery by providing an unbiased view of the hematopoietic system for target identification.
What quantitative measurements does mass cytometry enable for neutrophil-lineage analysis?
Mass cytometry provides high-dimensional quantification of 33 surface markers per single cell, enabling precise immunophenotyping. The viSNE algorithm clusters cells based on marker similarity, revealing subsets with coordinated expression patterns. These quantitative outputs allow comparison of neutrophil-lineage populations across conditions and genetic backgrounds.
Why are replication requirements important for cross-functional collaboration?
Standardized steps like red blood cell lysis, Fc blocking, and overnight fixation ensure consistent cell recovery and staining across replicates. Reproducible protocols allow immunology, pharmacology, and translational teams to compare data reliably. Consistent results build confidence in target validation and support multi-disciplinary decision-making in drug discovery programs.
What statistical analysis capabilities are required before implementing this protocol?
Implementation requires ability to perform dimensional reduction (e.g., viSNE) and clustering of high-dimensional CyTOF data. Users need expertise in gating strategies and marker co-expression analysis to identify rare populations. Access to open-source tools for visualization and statistical comparison of neutrophil-lineage subsets is essential for data interpretation.
